NCT07912996
Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Experiencing Adverse Events (AEs)
Timeframe: Enrollment up to 92 days
Percentage of Participants Experiencing Premature Study-Dug Discontinuation due to AEs
Timeframe: Enrollment up to 92 days
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Timeframe: First dose date up to 92 days
Herpes Simplex Virus Type 2 (HSV-2) Shedding Rate During the Swabbing Period
Timeframe: Day 8 to Day 38
Secondary (17)
Proportion of Participants Free of Genital Herpes Recurrences at Day 92
Proportion of Participants Free of Genital Herpes Recurrences at Day 120
Genital Herpes Lesion Rate During the Treatment Period
Genital Herpes Lesion Duration During the Treatment Period
Virologically Confirmed Genital Herpes Lesion Rate During the Treatment Period
Show 12 moreShow less
Virologically Confirmed Genital Herpes Lesion Duration During the Treatment Period
Time to Suppression of HSV-2 Shedding
Number of HSV-2 Shedding Episodes During the Swabbing Period
Duration of HSV-2 Shedding Episodes During the Swabbing Period
Proportion of Participants With Subclinical HSV-2 Shedding During the Swabbing Period
HSV-2 DNA (Copies/mL) for Swab Samples that are Positive for HSV-2 DNA During the Swabbing Period
HSV-2 DNA (Copies/mL) for Positive Swab Samples in the Absence of Lesions (Subclinical Shedding) During the Swabbing Period
Proportion of Swab Samples With HSV-2 DNA > 4 log10 Copies/mL for Positive Swab Samples During the Swabbing Period
Proportion of Swab Samples With HSV-2 DNA > 4 log10 Copies/mL for Positive Swab Samples in the Absence of Lesions (Subclinical Shedding) During the Swabbing Period
Plasma Pharmacokinetic (PK) Parameters: Cmax of GS-1179
Plasma PK Parameters: AUCtau of GS-1179
Plasma PK Parameters: Ctrough of GS-1179
Arms and interventions
GS-1179 High Dose + VACV Placebo to Match (PTM)Experimental
Participants will be randomized to receive a high-dose of GS-1179 once weekly up to 85 days and VACV PTM once daily up to 92 days.
GS-1179 Low Dose + VACV Placebo to Match (PTM)Experimental
Participants will be randomized to receive a low-dose of GS-1179 once weekly up to 85 days and VACV PTM once daily up to 92 days.
VACV + GS-1179 PTMActive comparator
Participants will be randomized to receive VACV once daily up to 92 days and GS-1179 PTM once weekly up to 85 days.
Drugs: GS-1179, GS-1179 PTM, Valacyclovir, Valacyclovir PTM